117449-73-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-phenylnicotinic acid is used as a precursor in the synthesis of new drugs, leveraging its unique chemical structure to create novel therapeutic agents. Its potential lies in the development of pharmaceuticals that target specific biological pathways or receptors, offering innovative treatment options for various diseases.
Used in Organic Chemistry Research:
2-Chloro-5-phenylnicotinic acid serves as a valuable research tool in the field of organic chemistry, enabling scientists to explore its reactivity, stability, and interactions with other molecules. 2-Chloro-5-phenylnicotinic acid can be utilized in the study of reaction mechanisms, the development of new synthetic methods, and the investigation of structure-activity relationships in drug design.
Used in Pharmacology Studies:
In pharmacology, 2-Chloro-5-phenylnicotinic acid is used as a probe to understand its biological activity and potential therapeutic effects. Researchers can employ 2-Chloro-5-phenylnicotinic acid to investigate its interactions with biological targets, such as enzymes, receptors, or ion channels, and assess its efficacy and safety in preclinical models of disease.
While the potential uses of 2-Chloro-5-phenylnicotinic acid are promising, further research and testing are essential to fully elucidate its applications and validate its safety and efficacy in practical settings.

Upstream product

• 10177-08-9 1,2-dihydro-2-oxo-5-phenyl-3-pyridinecarboxylic acid 
• 824-72-6 P,P-dichlorophenylphosphine oxide 

Downstream Products

• 117427-78-8 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methyl-7-phenylpyrido-[3,2-f]-1,4-oxazepine-5(4H)-thione 
• 117450-10-9 2-(2-chloroethyl)-3,4-dihydro-4-methyl-7-phenylpyrido<3,2-f>-1,4-oxazepine-5(2H)-thione 
• 117450-12-1 2-(2-chloroethyl)-3,4-dihydro-4-methyl-7-phenylpyrido<3,2-f>-1,4-oxazepin-5(2H)-one 
• 156896-58-1 C₁₂H₇Cl₂NOS 
• 85128-55-8 1,2-dihydro-5-phenyl-2-thioxo-3-pyridinecarboxylic acid 
• 162830-51-5 2-Chloro-5-phenyl-nicotinoyl chloride 
• 117450-21-2 2-<(1-methyl-3-pyrrolidinyl)oxy>-5-phenyl-3-pyridinecarboxylic acid sodium salt 

Relevant academic research and scientific papers

New 5H-[1,3]thiazolo[3,2-a]pyrido[3,2-e]pyrimidin-5-one derivatives as diuretics

A series of new 5H-[1,3]thiazolo[3,2-α]pyrido[3,2-e]pyrimidin-5-ones 3-substituted and/or 8,9-hydrogenated was prepared and tested for their diuretic, natriuretic and kaliuretic activities on male Wistar rats at a dosage of 25 mg/kg or less. Diuretic and saliuretic activities were strongly influenced by substituents in 3-position. Quantitative structure-activity relationships show that electron withdrawn substituents in 3-position enhance both diuretic and saliuretic activities at 25 mg/kg. Global analysis of the variations introduced on pyridine, pyrimidine and thiazole rings of this tricyclic system showed an increase of diuretic and natriuretic activities when the formal charge on N(9a) and C(9b) increases. Potassium ion excretion also increases, although not as drastically as in the earlier cases. Regression equations were calculated by partial least squares method (PLS) and validated by the cross-validation (leave-one-out) technique.

NEW 5-SUBSTITUTED DERIVATIVES OF ETHYL 2,3-DIHYDRO-3-OXOISOTHIAZOLOPYRIDINE-2-ACETATE

New series of ethyl 5-substituted 2,3-dihydro-3-oxoisothiazolopyridine-2-acetate was prepared either a) directly by reaction of 5-substituted 2-chlorothio-3-pyridinecarbonyl chlorides with ethyl glycinate or b) by oxidation of the correspondent 2-mercapto-3-pyridinecarboxamides.New 5-substituted 1,2-dihydro-2-thio-3-pyridinecarboxylic acids as starting materials are described.

Benzo- and pyrido-1,4-oxazepin-5-ones and -thiones: Synthesis and structure-activity relationships of a new series of H1 antihistamines

A series of novel benzo- and pyrido-1,4-oxazepinones and -thiones which represents a new structural class of compounds possessing H1 antihistaminic acitivy was synthesized, and the SARs were evaluated. The antihistamine activity was determined by blockade of histamine-induced lethality in guinea pigs. The sedative potential was determined by comparison of the EEG profiles of the compounds with those of known sedating and nonsedating antihistamines. Several of the compounds were shown to possess potent H1 antihistaminic activity and to be free of the cortical slowing with synchronized waves and spindling activity found in the EEG of sedative antihistamines. One compound, 2-[2-(dimethylamino)ethyl]-3,4-dihydro-4-methylpyrido[3,2-f]-1,4-oxazeN pine-5(2H)-thione (rocastine) is currently undergoing clinical evaluation as a nonsedating H1 antihistamine.

Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof

Aromatic azepinones and thiones having the formula STR1 wherein; A is benzene, naphthalene, quinoline or pyridine; B is oxygen or sulfur; E is oxygen, sulfur or STR2 n is 1, 2 or 3; Z is an amino or a heterocyclic nitrogen-containing radical; R is hydrogen, loweralkyl, cycloalkyl or phenylloweralkyl; Y is halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracetylamino, trifluoromethyl, phenyl or phenyl substituted by one to three Y' radicals selected from halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracylamino or trifluoromethyl; and having antihistaminic utility, a process for the preparation thereof and chemical intermediates therefor are disclosed.